Ascendis Pharma gains after Q3 beat and strong product sales growth

2026-11-12

Investivoq PriceTracker

Ascendis Pharma A/S (ASND) is up 3.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied mainly to a strong third-quarter report that showed revenue, earnings, and profitability improving faster than many investors expected. Strong growth from YORVIPATH, a swing to net profit, and upbeat cash-flow and pipeline updates likely reinforced the positive reaction.

Details:

Third-quarter 2026 product revenue rose 89% year over year to about €366 million, while total revenue increased to roughly €370 million.

Net profit reached about €74 million, or €1.08 per diluted share, compared with a loss in the prior-year period, and market estimates were exceeded on both earnings and revenue.

YORVIPATH remained the main growth driver, contributing about €291 million in quarterly revenue, with management also pointing to expanding demand outside the U.S.

The update also included positive regulatory momentum for TransCon CNP in Europe, a full-year operating cash-flow outlook of at least €600 million, and continued share repurchases through November 11.

Sources:

Ascendis Pharma, MarketBeat, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ASND Insider Trading Activity

$ASND insiders have traded $ASND stock on the open market 11 times in the past 6 months. Of those trades, 9 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $ASND stock by insiders over the last 6 months:

MADS BODENHOFF (SVP & PAO) sold 3,000 shares for an estimated $810,570
JEAN JACQUES BIENAIME has made 7 purchases buying 2,900 shares for an estimated $699,336 and 0 sales.
SCOTT THOMAS SMITH (EVP & Chief Financial Officer) has made 2 purchases buying 350 shares for an estimated $77,730 and 0 sales.
LARS HOLTUG sold 236 shares for an estimated $62,334

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

$ASND Hedge Fund Activity

We have seen 221 institutional investors add shares of $ASND stock to their portfolio, and 148 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 5,674,622 shares (+525.3%) to their portfolio in Q2 2026, for an estimated $1,513,535,179
BLACKROCK, INC. added 1,550,779 shares (+234.6%) to their portfolio in Q2 2026, for an estimated $413,623,774
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 596,164 shares (-18.5%) from their portfolio in Q2 2026, for an estimated $159,008,862
CAPITAL INTERNATIONAL INVESTORS removed 571,225 shares (-28.7%) from their portfolio in Q3 2026, for an estimated $130,142,191
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. removed 556,427 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $148,410,209
PRICE T ROWE ASSOCIATES INC /MD/ removed 407,816 shares (-26.6%) from their portfolio in Q2 2026, for an estimated $108,772,683
PERCEPTIVE ADVISORS LLC removed 367,700 shares (-24.0%) from their portfolio in Q2 2026, for an estimated $98,072,944

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$ASND Price Targets

Multiple analysts have issued price targets for $ASND recently. We have seen 2 analysts offer price targets for $ASND in the last 6 months, with a median target of $317.5.

Here are some recent targets:

Luca Issi from RBC Capital set a target price of $280.0 on 07/07/2026
Eric Joseph from Citigroup set a target price of $355.0 on 05/19/2026

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.